Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03398083 · ClinicalTrials.gov registry record · Phase 1
Evaluation of the Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam
A Phase 1 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT03398083 is a Phase 1 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 42 participants.
The verdict
NCT03398083, a Phase 1 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the abuse potential of CBD to determine whether it should remain as a Schedule I drug under the Controlled Substances Act, or be recommended for decontrol.
Interventions
- DRUG Alprazolam
- DRUG THC
- DRUG Placebo oral capsule
- DRUG CBD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2017-12-04 |
| Est. Completion | 2018-05-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03398083
The ClinicalTrials.gov registry entry for NCT03398083 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Alprazolam is the first listed.
NCT03398083 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03398083 about?
NCT03398083 is a clinical study titled "Evaluation of the Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam". The purpose of this study is to evaluate the abuse potential of CBD to determine whether it should remain as a Schedule I drug under the Controlled Substances Act, or be recommended for decontrol.
What is the current status of trial NCT03398083?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2017-12-04. Estimated completion is 2018-05-30.
What interventions are being tested in trial NCT03398083?
The interventions under investigation include: Alprazolam (DRUG), THC (DRUG), Placebo oral capsule (DRUG), CBD (DRUG).
Who is sponsoring clinical trial NCT03398083?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.